
Diabetes
Latest News
Latest Videos

More News

The FDA has approved Awiqli® (insulin icodec-abae), the first once-weekly basal insulin for adults with type 2 diabetes, reducing injections from 7 to 1 per week.

Replacing 30 minutes of sedentary time with sleep or exercise was linked to lower insulin resistance in teens in preliminary AHA EPI 2026 data.

FDA clears MiniMed Flex insulin pump with smartphone control and adaptive algorithm for type 1 and insulin-requiring type 2 diabetes.

ATTD 2026: Registry data from US primary care practices showed Dexcom G7 use lowered HbA1c by 0.7% over 1 year in adults with noninsulin-treated type 2 diabetes.

Phase 3 FINE-ONE shows finerenone cuts protein in urine for type 1 diabetes CKD patients, with manageable safety, hinting at new kidney protection.

The FDA issued 30 warning letters to telehealth firms for false or misleading claims about compounded GLP-1 products, citing illegal marketing practices.

New real-world evidence links GLP-1RAs to lower acute care use and fewer treatment escalations than topiramate for chronic migraine.

GLP‑1 therapy reduces asthma flare-ups in overweight non‑diabetics, suggesting a promising add-on for obesity-related asthma care.

FDA approves DESMODA, a ready-to-use desmopressin acetate oral solution, enabling precise titration for central diabetes insipidus with key hyponatremia warnings.

Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.

The FDA updates Afrezza's prescribing information, enhancing dosing guidance for adults switching from injected insulin to improve glycemic control.

A nephrology expert reviews how workflow constraints and care delivery pressures affect adherence to guideline-recommended responses to elevated urine albumin-to-creatinine ratio.

A nephrology expert discusses survey findings that reveal gaps between UACR testing and action in cardiovascular risk assessment for type 2 diabetes.

FDA prioritizes review of Tzield for young children with stage 2 type 1 diabetes, potentially delaying disease onset and improving patient outcomes.

CGM users experienced fewer ED and inpatient days and better glycemic outcomes, but most eligible adults in this large cohort did not use the technology.

The 2026 annual updates to the Standards of Care in Diabetes include wider CGM use, guidance on dosing of antiobesity drugs, and glycemic management during cancer therapy.

Insulet enhances the Omnipod® 5 system with new glucose targets and algorithms, improving insulin delivery for diabetes management.

GLORY-2 participants showed continuous weight loss through 60 weeks with no plateau; mazdutide also improved multiple cardiometabolic markers.

FDA approves Dexcom Smart Basal, a groundbreaking CGM-integrated insulin dosing optimizer, enhancing diabetes management for adults with Type 2 diabetes.

A new study reveals that the Preventive Health Inventory enhances diabetes and hypertension management among veterans without increasing hospitalizations.

Adults with diabetes often face obstacles to optimal disease management in the workplace. Use this checklist in the clinic to help them navigate the barriers.

Global survey data highlight persistent stigma and self-management barriers for adults with diabetes in the workplace, with implications for clinical care.

These 42 factors that affect blood glucose are in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.

Your daily dose of the clinical news you may have missed.

The real-world study of 200,000+ adults found no GI safety differences among 3 GLP-1 drugs for T2D, however SGLT-2 inhibitors are safer for motility issues.































































































































































